Press Releases Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06/12/2024			5-day change	1st Jan Change
180,100.00 ^KRW	-0.50%		-3.69%	-10.62%

12-05	Celltrion to Retire 3 Million Treasury Stock in January	MT
12-04	South Korea's FTC Slaps KRW435 Million Fine on Celltrion for Unfair Business Practices	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BPCIA Lawsuit Against Accord's Proposed Prolia® / Xgeva® Biosimilar Filed By Amgen	11-21	AQ
FDA Accepts ABLAs For Prolia® / Xgeva® Biosimilars From Organon And Teva	11-07	AQ
Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab, highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease	10-16	AQ
Amgen Files BPCIA Complaint Against Fresenius Kabi Regarding Denosumab	10-16	AQ
Celltrion Wins Brazilian Federal Tender For Trastuzumab For Fifth Consecutive Year	09-20	AQ
Recent PTAB Developments For Regeneron's Aflibercept-Dosing Patents	08-16	AQ
Preliminary Injunction Issued Against Samsung Bioepis In Aflibercept BPCIA Litigation	06-20	AQ
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab	06-10	AQ
European Biosimilar Regulatory Update	06-10	AQ
Celltrion - Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally	05-20	AQ
Celltrion USA announces two-year data for ZYMFENTRA(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference	05-20	AQ
Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders	05-16	AQ
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	04-22	AQ
Updates On Aflibercept BPCIA Litigation	03-26	AQ
Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S.	03-20	AQ
Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab)	03-05	AQ
PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent	02-29	AQ
Celltrion Submits An ABLA For Actemra® (Tocilizumab) Proposed Biosimilar CT-P47	02-29	AQ
Chugai, Genentech, And Hoffmann-La Roche Dismiss Appeals Of Actemra® Patent IPR Final Written Decisions	02-29	AQ
Updates On Aflibercept BPCIA Litigation	02-19	AQ
Celltrion Launches 80 Mg YUFLYMA (Adalimumab-aaty) In The U.S.	02-05	AQ
PTAB Issues Final Written Decisions Finding Claims Of Aflibercept-Related Patents Invalid	01-26	AQ
Celltrion presents strategic vision and growth plan at the 42nd Annual J.P. Morgan Healthcare Conference	01-12	AQ
Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation	01-11	AQ
Celltrion Completes Application For FDA Approval Of CT-P41, Biosimilar Of Prolia® / Xgeva®	01-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Press Releases

Filters